Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Prohibitin promotes dedifferentiation and is a potential therapeutic target in neuroblastoma
Ian C. MacArthur, … , Alex Kentsis, Anton G. Henssen
Ian C. MacArthur, … , Alex Kentsis, Anton G. Henssen
Published April 18, 2019
Citation Information: JCI Insight. 2019;4(10):e127130. https://doi.org/10.1172/jci.insight.127130.
View: Text | PDF
Research Article Genetics Oncology

Prohibitin promotes dedifferentiation and is a potential therapeutic target in neuroblastoma

  • Text
  • PDF
Abstract

Gain of the long arm of chromosome 17 (17q) is a cytogenetic hallmark of high-risk neuroblastoma, yet its contribution to neuroblastoma pathogenesis remains incompletely understood. Combining whole-genome and RNA sequencing of neuroblastomas, we identified the prohibitin (PHB) gene as highly expressed in tumors with 17q gain. High PHB expression correlated with poor prognosis and was associated with loss of gene expression programs promoting neuronal development and differentiation. PHB depletion induced differentiation and apoptosis and slowed cell cycle progression of neuroblastoma cells, at least in part through impaired ERK1/2 activation. Conversely, ectopic expression of PHB was sufficient to increase proliferation of neuroblastoma cells and was associated with suppression of markers associated with neuronal differentiation and favorable neuroblastoma outcome. Thus, PHB is a 17q oncogene in neuroblastoma that promotes tumor cell proliferation and dedifferentiation.

Authors

Ian C. MacArthur, Yi Bei, Heathcliff Dorado Garcia, Michael V. Ortiz, Joern Toedling, Filippos Klironomos, Jana Rolff, Angelika Eggert, Johannes H. Schulte, Alex Kentsis, Anton G. Henssen

×

Figure 4

PHB knockdown promotes differentiation of neuroblastoma cells.

Options: View larger image (or click on image) Download as PowerPoint
PHB knockdown promotes differentiation of neuroblastoma cells.
(A) Photo...
(A) Photomicrographs of Kelly cells after transduction with shRNAs against either PHB or GFP. Photomicrographs representative of 3 independent samples. (B) NTRK1 and NGFR mRNA expression measured by quantitative reverse transcription PCR (qRT-PCR) after PHB knockdown. Data represent mean ± SEM. n = 3, *P < 0.001, 2-tailed t test. (C) Heatmap showing significantly differentially expressed genes in IMR-5/75 after PHB knockdown. PHB, NTRK1, and NGFR are labeled in bold and denoted by arrowheads. n = 3, and P < 0.001. (D) GO analysis of differentially expressed genes after PHB knockdown. n = 3, Fisher’s exact test. (E) GSEA plot of neuronal differentiation after PHB knockdown. n = 3, Fisher’s exact test. Stated n values indicate number of biological replicates.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts